Systematic Review on Curcuma longa vs. Acarbose for Diabetes Mellitus Prevention in Patients with Impaired Fasting Glucose

Main Article Content

Thanawat Wongphan
Sermsiripoca Sermsiripoca
Krit Pongpirul
Duangkaew Panyaphu
Jitisak Poonsrisawat
Pratchayanan Poonniam
Phanupong Phutrakool
Jindaporn Puripattanavong

Abstract

Introduction and objectives: Diabetes mellitus (DM) is one of the leading causes of mortality and morbidity
in Thailand. There are multiple methods for helping people to prevent DM such as lifestyle modification, modern drug medication, and herbal therapy. Turmeric (C. longa) extract, or curcumin, is one of the herbal remedies that can decrease the incidence of DM and cardiovascular disease like anti-diabetic drug acarbose. This study aimed to explore and compare the efficacy of curcumin and acarbose. Methodology: Systemic review was done according to the PRISMA protocol. Three databases were used, including PubMed®, Scopus® and Web of sciences®. Results: Totally, 115 publications were retrieved from the databases but only two were selected. The review found no direct efficacy comparison between curcumin and acarbose, but curcumin could decrease DM incidence by 16.4% and aided patients to decrease their BMI by 6.43%. Whereas, acarbose could decrease DM incidence to 32%; however, 25% of these patients dropped out of the trial. Discussion: Even though curcumin and acarbose are effective in decreasing new DM cases, acarbose showed a high dropout rate; and there have been no studies on the effect of curcumin on human blood vessels. So a complete comparison could not be undertaken. Conclusions: Both curcumin and acarbose have the potential to decrease DM incidence, but direct efficacy comparison is lacking.
Thus, comparative studies on this matter should be done in the future.

Downloads

Download data is not yet available.

Article Details

Section
Original Articles

References

Bundhamcharoen K, Odton P, Phulkerd S, Tangcharoensathien V. Burden of disease in Thailand: changes in

health gap between 1999 and 2004. BMC Public Health. 2011;11:53.

American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2016;39(Suppl

:S13-22.

Rao SS, Disraeli P, McGregor T. Impaired glucose tolerance and impaired fasting glucose. Am Fam Physician.

;69(8):1961-8.

Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B, American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care.

;30(3):753-9.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High

Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education

Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults

(adult treatment panel III) final report. Circulation. 2002;106(25):3143-421.

Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231-7.

Investigators DT, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B,

Laakso M, Mohan V, Shaw J, Zinman B, Holman R R. Effect of rosiglitazone on the frequency of diabetes in

patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet.

;368(9541):1096-105.

Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN,

Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological

treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796-803.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group.

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet.

;359(9323):2072-7.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired

glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-94.

Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin

extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121-7.

Zheng B, Yang L, Wen C, Huang X, Xu C, Lee KH, Xu J. Curcumin analog L3 alleviates diabetic atherosclerosis

by multiple effects. Eur J Pharmacol. 2016;775:22-34.

Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes. 2012;5:357-67.

Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its

miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283-99.

Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787-809.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises.

Mol Pharm. 2007;4(6):807-18.

Devassy JG, Nwachukwu ID, Jones PJ. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev.

;73(3):155-65.

ClinicalTrials.gov. Improved oral bioavailability of curcumin incorporated into micelles. [Internet]. [cited

Jan 19]; Available from: https://clinicaltrials.gov/ct2/show/NCT01982734?term=curcumin&rank=5.

Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evid Based Complement

Alternat Med. 2013;2013:636053.

El-Azab MF, Attia FM, El-Mowafy AM. Novel role of curcumin combined with bone marrow transplantation in

reversing experimental diabetes: Effects on pancreatic islet regeneration, oxidative stress, and inflammatory

cytokines. Eur J Pharmacol. 2011;658(1):41-8.

El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SF, Ahmed AF. The antihyperglycemic effect of curcumin in high

fat diet fed rats. Role of TNF-alpha and free fatty acids. Food Chem Toxicol. 2011;49(5):1129-40.

Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki

K, Kawachi H, Watanabe K. Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation

and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond).

;8(1):35.

Suryanarayana P, Satyanarayana A, Balakrishna N, Kumar PU, Reddy GB. Effect of turmeric and curcumin

on oxidative stress and antioxidant enzymes in streptozotocin-induced diabetic rat. Med Sci Monit.

;13(12):BR286-92.

Chougala MB, Bhaskar JJ, Rajan MG, Salimath PV. Effect of curcumin and quercetin on lysosomal enzyme

activities in streptozotocin-induced diabetic rats. Clin Nutr. 2012;31(5):749-55.

Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T,

Nakagawa K, Kitahara M. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an

increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem. 2005;53(4):959-63.

Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, Lee MK. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res. 2008;52(9):995-1004.

He HJ, Wang GY, Gao Y, Ling WH, Yu ZW, Jin TR. Curcumin attenuates Nrf2 signaling defect, oxidative

stress in muscle and glucose intolerance in high fat diet-fed mice. World J Diabetes. 2012;3(5):94-104.

National Drug System Development Committee. National Lists of Essential Medicine B.E. 2549. [Internet].

[cited 2019 Apr 26]; Available from: http://drug.fda.moph.go.th:81/nlem.in.th/sites/default/files/binder3.pdf.

Xu K, Al-Ani MK, Pan X, Chi Q, Dong N, Qiu X. Plantderived products for treatment of vascular intima

hyperplasia selectively inhibit vascular smooth muscle cell functions. Evid Based Complement Alternat Med.

;2018:3549312.

Rashid Jusoh A, Das S, Kamsiah J, Qodriyah HM, Faizah O. Effect of curcumin on aortic changes in

ovariectomized rats fed with repeatedly heated soy oil: a preliminary electron microscopic study. Clin Ter.

;164(4):307-13.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group.

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Syst Rev. 2015;4(1):1.

Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or

prevent type 2 diabetes. Diabetes Care. 2005;28(3):736-44.

Yang W LL, Qi J. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentre prospective study. Chin J Endocrinol Metab. 2001;17:131-6.

Lettieri JT, Dain B. Effects of beano on the tolerability and pharmacodynamics of acarbose. Clin Ther.

;20(3):497-504.

Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of

atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J

Nutr Biochem. 2014;25(2):144-50.